Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Coll Cardiol. 2014 Apr 15;63(14):1430-7. doi: 10.1016/j.jacc.2014.01.031. Epub 2014 Feb 19.

Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome.

Author information

  • 1Department of Medicine, Vanderbilt University, Nashville, Tennessee; Department of Cardiology, Copenhagen University Hospital, Gentofte, Denmark.
  • 2Department of Medicine, Vanderbilt University, Nashville, Tennessee.
  • 3Department of Genome Sciences, University of Washington, Seattle, Washington.
  • 4Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • 5Vanderbilt Technologies for Advanced Genomics Analysis and Research Design, Nashville, Tennessee.
  • 6The Genome Institute, Washington University, St. Louis, Missouri.
  • 7Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, Tennessee.
  • 8Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, Tennessee. Electronic address: dan.roden@vanderbilt.edu.

Abstract

OBJECTIVES:

The aim of this study was to test the hypothesis that rare variants are associated with drug-induced long QT interval syndrome (diLQTS) and torsades de pointes.

BACKGROUND:

diLQTS is associated with the potentially fatal arrhythmia torsades de pointes. The contribution of rare genetic variants to the underlying genetic framework predisposing to diLQTS has not been systematically examined.

METHODS:

We performed whole-exome sequencing on 65 diLQTS patients and 148 drug-exposed control subjects of European descent. We used rare variant analyses (variable threshold and sequence kernel association test) and gene-set analyses to identify genes enriched with rare amino acid coding (AAC) variants associated with diLQTS. Significant associations were reanalyzed by comparing diLQTS patients with 515 ethnically matched control subjects from the National Heart, Lung, and Blood Grand Opportunity Exome Sequencing Project.

RESULTS:

Rare variants in 7 genes were enriched in the diLQTS patients according to the sequence kernel association test or variable threshold compared with drug-exposed controls (p < 0.001). Of these, we replicated the diLQTS associations for KCNE1 and ACN9 using 515 Exome Sequencing Project control subjects (p < 0.05). A total of 37% of the diLQTS patients also had 1 or more rare AAC variants compared with 21% of control subjects (p = 0.009), in a pre-defined set of 7 congenital long QT interval syndrome (cLQTS) genes encoding potassium channels or channel modulators (KCNE1, KCNE2, KCNH2, KCNJ2, KCNJ5, KCNQ1, AKAP9).

CONCLUSIONS:

By combining whole-exome sequencing with aggregated rare variant analyses, we implicate rare variants in KCNE1 and ACN9 as risk factors for diLQTS. Moreover, diLQTS patients were more burdened by rare AAC variants in cLQTS genes encoding potassium channel modulators, supporting the idea that multiple rare variants, notably across cLQTS genes, predispose to diLQTS.

Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

adverse drug event; exome; genetics; long QT interval syndrome; torsade des pointes

PMID:
24561134
[PubMed - indexed for MEDLINE]
PMCID:
PMC4018823
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk